163 related articles for article (PubMed ID: 1173561)
1. Placental transmission of thyroid-stimulating immunoglobulins.
Dirmikis SM; Munro DS
Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
[TBL] [Abstract][Full Text] [Related]
2. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
3. The role of thyroid stimulating immunoglobulins of Graves's disease in neonatal thyrotoxicosis.
Munro DS; Dirmikis SM; Humphries H; Smith T; Broadhead GD
Br J Obstet Gynaecol; 1978 Nov; 85(11):837-43. PubMed ID: 581471
[No Abstract] [Full Text] [Related]
4. Letter: Placental transmission of L. A. T. S. protector.
Dirmikis SM; Munro DS; Hiller EJ; Crawford MJ; Wynne J; Purcell M
Lancet; 1974 Dec; 2(7896):1579-80. PubMed ID: 4141025
[No Abstract] [Full Text] [Related]
5. The role of long acting thyroid stimulator in neonatal thyrotoxicosis.
Maisey MN; Stimmler L
Clin Endocrinol (Oxf); 1972 Jan; 1(1):81-90. PubMed ID: 4677121
[No Abstract] [Full Text] [Related]
6. Neonatal thyrotoxicosis: alterations in serum concentrations of LATS-protector, T4, T3, reverse T3, and 3,3'T2.
Smallridge RC; Wartofsky L; Chopra IJ; Marinelli PV; Broughton RE; Dimond RC; Burman KD
J Pediatr; 1978 Jul; 93(1):118-20. PubMed ID: 650321
[No Abstract] [Full Text] [Related]
7. Humoral and genetic factors in thyrotoxic Graves disease and neonatal thyrotoxicosis.
Green WL
JAMA; 1976 Apr; 235(14):1449-50. PubMed ID: 946443
[No Abstract] [Full Text] [Related]
8. ["Long-acting thyroid stimulator" and thyrotropic hormone in thyrotoxicosis in newborn infants].
Gautier E; Juillard E; Lemarchand-Béraud T
Schweiz Med Wochenschr; 1968 Jan; 98(1):8-12. PubMed ID: 5695264
[No Abstract] [Full Text] [Related]
9. [Non-fatal case of neonatal thyrotoxicosis with serial determination of LATS].
Tsuji A; Koshimizu T; Kato K
Horumon To Rinsho; 1970 May; 18(5):417-20. PubMed ID: 5465536
[No Abstract] [Full Text] [Related]
10. Neonatal thyrotoxicosis is associated with transplacental passage of human thyroid stimulating immunoglobulin (HTSI).
Mitchell I; Shenfield G; Brash J
Arch Dis Child; 1976 Jul; 51(7):565-7. PubMed ID: 962368
[TBL] [Abstract][Full Text] [Related]
11. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
12. Thyrotoxicosis detected in a mass-screening program for neonatal hypothyroidism: demonstration of placental transfer of an immunoglobulin with marked lipolytic activity.
Walker P; Dussault JH; Hart IR; Langelier P; Szöts F
J Pediatr; 1977 Sep; 91(3):400-3. PubMed ID: 894408
[TBL] [Abstract][Full Text] [Related]
13. Letter: Neonatal hyperthyroidism and long-acting thyroid stimulator protector.
Thomson JA; Dirmikis DS; Munro DS; Smith BR; Hall R; Mukhtar ED
Br Med J; 1975 Apr; 2(5961):36. PubMed ID: 1169089
[No Abstract] [Full Text] [Related]
14. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
Hardisty CA; Talbot CH; Munro DS
Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
[TBL] [Abstract][Full Text] [Related]
15. Neonatal transient thyrotoxicosis resulting from maternal TSH-binding inhibitor immunoglobulins.
Yagi H; Takeuchi M; Nagashima K; Suzuki S; Kuroume T; Iida Y; Konishi J; Endo K
J Pediatr; 1983 Oct; 103(4):591-3. PubMed ID: 6137525
[No Abstract] [Full Text] [Related]
16. Neonatal thyrotoxicosis with long acting thyroid stimulator-protector.
O'Hearlihy C
Ir Med J; 1977 Mar; 70(4):124-5. PubMed ID: 576864
[No Abstract] [Full Text] [Related]
17. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism].
Lamberg BA; Gordin A
Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398
[No Abstract] [Full Text] [Related]
18. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
Kendall-Taylor P
Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
[TBL] [Abstract][Full Text] [Related]
19. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
20. Isoelectric focusing of long-acting thyroid stimulator (LATS) containing IgG.
Schleusener H; Adlkofer F; Uher L; Kaper-Czygan S; Kirstaedter HJ
Horm Metab Res; 1971 May; 3(3):221-2. PubMed ID: 5171402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
